Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic disease
Biotech
Amgen disappears lung disease program after phase 2 fail
Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any primary or secondary endpoints.
Gabrielle Masson
Oct 30, 2024 5:59pm
Qiagen, AstraZeneca expand DNA test collaboration beyond cancer
Aug 29, 2024 11:30am
Eli Lilly charts 2nd space trip with Redwire
Mar 12, 2024 9:44am
Califf says pharma should prioritize chronic disease, addiction
Aug 25, 2022 2:00pm
